Published in Mov Disord on November 15, 2010
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
Brain amyloid and cognition in Lewy body diseases. Mov Disord (2012) 1.87
β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord (2012) 1.69
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology (2013) 1.53
CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology (2015) 1.45
Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging (2011) 1.40
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol (2012) 1.26
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther (2011) 1.07
Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology (2012) 1.04
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol (2013) 1.00
Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain (2012) 0.97
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol (2014) 0.94
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry (2014) 0.94
PET/CT in diagnosis of dementia. Ann N Y Acad Sci (2011) 0.89
Amyloid PET imaging: applications beyond Alzheimer's disease. Clin Transl Imaging (2015) 0.88
Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging (2014) 0.88
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord (2015) 0.87
Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. J Nucl Med (2013) 0.86
Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann Neurol (2014) 0.83
Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis (2012) 0.82
Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease. Mov Disord (2015) 0.81
Cognitive reserve and β-amyloid pathology in Parkinson disease. Parkinsonism Relat Disord (2015) 0.80
The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. Mov Disord (2012) 0.78
Molecular imaging of Alzheimer disease pathology. AJNR Am J Neuroradiol (2014) 0.78
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain (2016) 0.77
Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes. Clin Transl Imaging (2015) 0.77
An update on brain imaging in parkinsonian dementia. Imaging Med (2012) 0.77
Neuroimaging, biomarkers, and management of dementia with lewy bodies. Front Neurol (2013) 0.76
White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging (2015) 0.76
Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Mov Disord Clin Pract (2016) 0.75
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener (2017) 0.75
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res (1983) 41.26
Parkinsonism: onset, progression and mortality. Neurology (1967) 36.06
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab (1996) 9.49
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci (2000) 6.54
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem (2003) 5.34
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol (2005) 3.31
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology (2006) 2.17
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology (2004) 2.12
Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. Am J Med Genet (1999) 1.86
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology (2010) 1.58
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging (2004) 1.44
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
What causes mental dysfunction in Parkinson's disease? Mov Disord (2003) 1.27
Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord (2003) 1.27
Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord (2004) 1.27
[11C]PIB binding in Parkinson's disease dementia. Neuroimage (2007) 1.24
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A (2009) 4.18
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol (2006) 3.00
TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol (2007) 2.97
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Resting state functional connectivity of the striatum in Parkinson's disease. Brain (2012) 2.53
Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol (2006) 2.43
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The impact of litigation on neurologic research. Neurology (2006) 2.03
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol (2012) 1.82
Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care (2007) 1.82
Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes (2013) 1.78
Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem (2002) 1.70
Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol (2010) 1.66
Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes (2008) 1.65
The focal dystonias: current views and challenges for future research. Mov Disord (2013) 1.62
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci U S A (2007) 1.57
TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol (2009) 1.56
Task-specific dystonias: a review. Ann N Y Acad Sci (2008) 1.54
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology (2013) 1.53
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
Cervical carotid and circle of willis arterial anatomy of macaque monkeys: a comparative anatomy study. Anat Rec (Hoboken) (2009) 1.47
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol (2012) 1.44
Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. Brain Res Mol Brain Res (2003) 1.44
Oromandibular and lingual dystonia associated with spinocerebellar ataxia type 8. Mov Disord (2012) 1.44
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Psychological processes underlying risky decisions in drug abusers. Psychol Addict Behav (2005) 1.40
Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord (2006) 1.36
Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. Alzheimer Dis Assoc Disord (2007) 1.35
Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg (2008) 1.31
VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. J Biol Chem (2009) 1.31
Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat (2008) 1.30
Prospectively determined impact of type 1 diabetes on brain volume during development. Diabetes (2011) 1.27
Predictors of survival in patients with Parkinson disease. Arch Neurol (2012) 1.27
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol (2012) 1.26
The quantification of gene expression in an animal model of brain ischaemia using TaqMan real-time RT-PCR. Brain Res Mol Brain Res (2002) 1.26
Mapping Go-No-Go performance within the subthalamic nucleus region. Brain (2010) 1.26
Effect of stimulation frequency on tremor suppression in essential tremor. Mov Disord (2004) 1.26
Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol (2010) 1.26
Increased risk of parkinsonism associated with welding exposure. Neurotoxicology (2012) 1.23
A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci U S A (2002) 1.22
Parkinson disease is not associated with C9ORF72 repeat expansions. Neurobiol Aging (2012) 1.22
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol (2014) 1.21
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders. Occup Environ Med (2012) 1.17
Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology (2012) 1.17
Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care (2013) 1.17
TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol (2008) 1.16
Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun (2013) 1.15
White matter microstructural integrity in youth with type 1 diabetes. Diabetes (2012) 1.15
High-throughput mutational analysis of TOR1A in primary dystonia. BMC Med Genet (2009) 1.14
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement (2012) 1.14
Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm (Vienna) (2009) 1.14
Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci (2010) 1.12
Haplotypes extending across ACE are associated with Alzheimer's disease. Hum Mol Genet (2003) 1.11
[18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov Disord (2005) 1.11
Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch Neurol (2007) 1.11
Overlap between neurodegenerative disorders. Neuropathology (2005) 1.10
Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology (2013) 1.10
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol (2014) 1.08
A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol. Synapse (2013) 1.07
Gait and balance in essential tremor: variable effects of bilateral thalamic stimulation. Mov Disord (2009) 1.06
Dopaminergic modulation of response inhibition: an fMRI study. Brain Res Cogn Brain Res (2004) 1.06
Preexisting cognitive impairment in women before cardiac surgery and its relationship with C-reactive protein concentrations. Anesth Analg (2006) 1.06
Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat (2004) 1.06
Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. Brain Res Mol Brain Res (2003) 1.06